HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

10 أكتوبر 2022 04:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022 Presentation

07 سبتمبر 2022 18:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022

23 أغسطس 2022 04:30:00 بحسب Nasdaq GlobeNewswire

Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004

09 أغسطس 2022 04:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial

08 أغسطس 2022 06:01:59 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer

07 أغسطس 2022 20:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China

15 يوليو 2022 04:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting

12 يوليو 2022 20:00:00 بحسب Nasdaq GlobeNewswire

Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007

06 يوليو 2022 00:40:34 بحسب Nasdaq GlobeNewswire

HUTCHMED to Announce 2022 Half-Year Financial Results

27 يونيو 2022 04:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China

01 يونيو 2022 04:33:07 بحسب Nasdaq GlobeNewswire

Appointment of Non–Executive Director

16 مايو 2022 07:00:02 بحسب Nasdaq GlobeNewswire

HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

02 مايو 2022 06:00:00 بحسب Nasdaq GlobeNewswire

Update on Status under Holding Foreign Companies Accountable Act

31 مارس 2022 00:00:00 بحسب Nasdaq GlobeNewswire

Update on Status under Holding Foreign Companies Accountable Act

11 مارس 2022 04:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS® in Lung Cancer

06 مارس 2022 23:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED announces retirement of CEO and appointment of new CEO

03 مارس 2022 07:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Reports 2021 Full Year Results and Provides Business Updates

03 مارس 2022 07:00:01 بحسب Nasdaq GlobeNewswire

HUTCHMED Receives Approval to Commercialize ELUNATE® in Macau

01 مارس 2022 03:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED to Announce 2021 Final Results

07 فبراير 2022 03:30:00 بحسب Nasdaq GlobeNewswire